Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Clinical_Trials
|
| gptkbp:aims_to_improve |
cardiovascular outcomes
|
| gptkbp:challenges |
patient recruitment
|
| gptkbp:collaborated_with |
international research teams
|
| gptkbp:completed |
gptkb:2018
|
| gptkbp:concluded_on |
positive findings
|
| gptkbp:conducted |
multiple countries
research institutions strict regulatory guidelines |
| gptkbp:has_ethical_approval |
institutional review boards
|
| gptkbp:has_exclusion_criteria |
history of hypersensitivity to study drug
|
| gptkbp:has_follow_up_period |
up to 5 years
|
| gptkbp:has_inclusion_criteria |
age 40 years or older
|
| gptkbp:has_primary_outcome |
time to first major cardiovascular event
|
| gptkbp:has_secondary_outcome |
hospitalization for unstable angina
|
| https://www.w3.org/2000/01/rdf-schema#label |
FOURIER Trial
|
| gptkbp:includes |
placebo group
|
| gptkbp:involves_intervention |
evolocumab administration
|
| gptkbp:is_analyzed_in |
statistical methods
safety and efficacy long-term effects meta-analyses. |
| gptkbp:is_associated_with |
improved patient outcomes
|
| gptkbp:is_cited_in |
subsequent research studies
|
| gptkbp:is_collaborative_with |
other clinical trials
|
| gptkbp:is_discussed_in |
healthcare policy debates
|
| gptkbp:is_documented_in |
clinical trial registries
|
| gptkbp:is_evaluated_by |
health economists
|
| gptkbp:is_influenced_by |
previous studies on statins
|
| gptkbp:is_influential_in |
guidelines for cardiovascular disease management
|
| gptkbp:is_linked_to |
reduction in heart attacks
|
| gptkbp:is_noted_for |
its large sample size
|
| gptkbp:is_part_of |
evidence-based medicine
larger studies on lipid-lowering therapies clinical research on PCSK9 inhibitors |
| gptkbp:is_referenced_in |
systematic reviews
|
| gptkbp:is_related_to |
cholesterol management
hyperlipidemia |
| gptkbp:is_reviewed_by |
gptkb:healthcare_professionals
|
| gptkbp:is_significant_for |
cardiology research
|
| gptkbp:is_supported_by |
patient advocacy groups
grants from health organizations funding from pharmaceutical companies |
| gptkbp:is_utilized_for |
clinical decision-making
|
| gptkbp:is_utilized_in |
medical education
|
| gptkbp:measures |
LDL cholesterol levels
|
| gptkbp:outcome |
reduced cardiovascular events
|
| gptkbp:participants |
patients with atherosclerotic cardiovascular disease
|
| gptkbp:published_by |
peer-reviewed journals
|
| gptkbp:published_in |
gptkb:New_England_Journal_of_Medicine
|
| gptkbp:registration |
gptkb:Clinical_Trials.gov
|
| gptkbp:reported_by |
gptkb:media_outlets
medical conferences |
| gptkbp:research |
gptkb:evolocumab
|
| gptkbp:sponsored_by |
gptkb:Amgen
|
| gptkbp:started_in |
gptkb:2013
|
| gptkbp:uses |
randomized controlled design
|